204 related articles for article (PubMed ID: 36869304)
1. Clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
Pang L; Xie M; Ma X; Huang A; Song J; Yao J; Deng H; Zhang D; Zang X; Ren F; Gao J; Wu C; Wang Y; Zhang X; Bao X; Pan L; Xue X
BMC Cancer; 2023 Mar; 23(1):203. PubMed ID: 36869304
[TBL] [Abstract][Full Text] [Related]
2. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis.
Huang A; Xu Y; Zang X; Wu C; Gao J; Sun X; Xie M; Ma X; Deng H; Song J; Ren F; Pang L; Qian J; Yu Z; Wan S; Chen Y; Pan L; Zhuang G; Liu S; Xue X
BMC Cancer; 2021 May; 21(1):634. PubMed ID: 34051746
[TBL] [Abstract][Full Text] [Related]
3. [Clinical features and prognostic analysis of checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer].
Chen RX; Liu XN; Xu Y; Shi YJ; Wang MQ; Shao C; Huang H; Xu K; Wang MZ; Xu ZJ
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Mar; 47(3):207-213. PubMed ID: 38448169
[No Abstract] [Full Text] [Related]
4. Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study.
Wang H; Zhao Y; Zhang X; Si X; Song P; Xiao Y; Yang X; Song L; Shi J; Zhao H; Zhang L
Cancer Med; 2021 Jan; 10(1):188-198. PubMed ID: 33211395
[TBL] [Abstract][Full Text] [Related]
5. [Clinical and chest CT features of immune checkpoint inhibitor-related pneumonitis].
Zhang Q; Zhao SJ; Wang SH; Tao XL; Wu N
Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):182-187. PubMed ID: 36781241
[No Abstract] [Full Text] [Related]
6. Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease.
Zeng Z; Qu J; Yao Y; Xu F; Lu S; Zhang P; Yao Y; Li N; Zhou J; Wang Y
BMC Pulm Med; 2022 Dec; 22(1):458. PubMed ID: 36456932
[TBL] [Abstract][Full Text] [Related]
7. Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer.
Moda M; Saito H; Kato T; Usui R; Kondo T; Nakahara Y; Murakami S; Yamamoto K; Yamada K
Thorac Cancer; 2020 Dec; 11(12):3576-3584. PubMed ID: 33078531
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus infection as an underestimated trigger for checkpoint inhibitor-related pneumonitis in lung cancer: a retrospective study.
Lin X; Lu T; Li S; Xie X; Chen X; Jiang J; Qin Y; Xie Z; Liu M; Ouyang M; Zhong N; Song Y; Zhou C
Clin Transl Oncol; 2021 Feb; 23(2):389-396. PubMed ID: 32613413
[TBL] [Abstract][Full Text] [Related]
9. Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.
Suresh K; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; D'Alessio F; Hales RK; Lin CT; Psoter KJ; Danoff SK; Naidoo J
J Thorac Oncol; 2018 Dec; 13(12):1930-1939. PubMed ID: 30267842
[TBL] [Abstract][Full Text] [Related]
10. Quantification of preexisting lung ground glass opacities on CT for predicting checkpoint inhibitor pneumonitis in advanced non-small cell lung cancer patients.
Wang X; Zhao J; Mei T; Liu W; Chen X; Wang J; Jiang R; Ye Z; Huang D
BMC Cancer; 2024 Feb; 24(1):269. PubMed ID: 38408928
[TBL] [Abstract][Full Text] [Related]
11. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.
Tone M; Izumo T; Awano N; Kuse N; Inomata M; Jo T; Yoshimura H; Minami J; Takada K; Miyamoto S; Kunitoh H
Thorac Cancer; 2019 Oct; 10(10):2006-2012. PubMed ID: 31482678
[TBL] [Abstract][Full Text] [Related]
12. Risk Factors for Immune Checkpoint Inhibitor-Related Pneumonitis in Cancer Patients: A Systemic Review and Meta-Analysis.
Zhou P; Zhao X; Wang G
Respiration; 2022; 101(11):1035-1050. PubMed ID: 36108598
[TBL] [Abstract][Full Text] [Related]
13. Anti‑PD‑1/PD‑L1 and anti‑CTLA‑4 associated checkpoint inhibitor pneumonitis in non‑small cell lung cancer: Occurrence, pathogenesis and risk factors (Review).
Hu X; Ren J; Xue Q; Luan R; Ding D; Tan J; Su X; Yang J
Int J Oncol; 2023 Nov; 63(5):. PubMed ID: 37681488
[TBL] [Abstract][Full Text] [Related]
14. Clinical Manifestation, Risk Factors, and Immune Checkpoint Inhibitor Rechallenge of Checkpoint Inhibitor-Associated Pneumonitis in Patients With Lung Cancer.
Li X; Yang F; Liu B; Ye L; Du J; Fan X; Yu Y; Li M; Bu L; Zhang Z; Xie L; Li W; Qi J
J Immunother; 2024 Jul-Aug 01; 47(6):220-226. PubMed ID: 38618919
[TBL] [Abstract][Full Text] [Related]
15. Recurrent and atypical immune checkpoint inhibitor-induced pneumonitis.
Jeon WJ; Nguyen J; Castillo DR; Park K; Brothers J; Nguyen A; Mirshahidi H
J Oncol Pharm Pract; 2023 Jul; 29(5):1264-1267. PubMed ID: 36648206
[TBL] [Abstract][Full Text] [Related]
16. The association between the incidence risk of pneumonitis and PD-1/PD-L1 inhibitors in advanced NSCLC: A meta-analysis of randomized controlled trials.
Lin GF; Xu Y; Lin H; Yang DY; Chen L; Huang LL; Su XS; Xu YX; Zeng YM
Int Immunopharmacol; 2021 Oct; 99():108011. PubMed ID: 34426108
[TBL] [Abstract][Full Text] [Related]
17. Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies.
Guo X; Chen S; Wang X; Liu X
Front Immunol; 2023; 14():1138483. PubMed ID: 37081866
[TBL] [Abstract][Full Text] [Related]
18. Distinguishing immune checkpoint inhibitor-related pneumonitis from radiation pneumonitis by CT radiomics features in non-small cell lung cancer.
Peiliang Wang MD; Yikun Li MM; Mengyu Zhao MM; Jinming Yu MD; Feifei Teng MD
Int Immunopharmacol; 2024 Feb; 128():111489. PubMed ID: 38266450
[TBL] [Abstract][Full Text] [Related]
19. Management, risk factors and prognostic impact of checkpoint-inhibitor pneumonitis (CIP) in lung cancer - A multicenter observational analysis.
Frost N; Unger K; Blum TG; Misch D; Kurz S; Lüders H; Olive E; Raspe M; Hilbrandt M; Koch M; Böhmer D; Senger C; Witzenrath M; Grohé C; Bauer T; Modest DP; Kollmeier J
Lung Cancer; 2023 May; 179():107184. PubMed ID: 37040677
[TBL] [Abstract][Full Text] [Related]
20. Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy.
Suresh K; Psoter KJ; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; Hales RK; D'Alessio F; Danoff SK; Naidoo J
J Thorac Oncol; 2019 Mar; 14(3):494-502. PubMed ID: 30503891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]